Skip to main content

Advertisement

Log in

Mutational Diversity of Lung Cancer and Associated Lymph Nodes. An Exploratory Prospective Study of 4 Resected cIIIA-N2

  • Original Article
  • Published:
Pathology & Oncology Research

Abstract

Mutational heterogeneity could explain different metastatic patterns among IIIA-N2 lung cancer and influence prognosis. The identification of subclonal mutations using deep sequencing to evaluate the degree of molecular heterogeneity may improve IIIA-N2 classification. The aim of this prospective study was to assess mutational and immunohistochemical characteristics in primary tumours and involved lymph nodes (LN) in operated patients. Four patients operated for primary lung carcinoma and unisite N2 mediastinal involvement were consecutively selected. Samples (tumour and paired LN) were analysed for PD1, PD-L1 and CD8 immunostaining. Somatic mutation testing was performed by deep targeted next generation sequencing (NGS), with the AmpliSeq™ Colon and Lung Cancer Panel (LifeTechnology). A total of 9 primary lung cancer samples and 10 LN stations were analysed. For each cancer, we found 2 mutations, with allelic ratios from 3% to 72%. Mutational patterns were heterogeneous for 2 primary tumours. In 3 cases, mutations observed in the primary tumour were not found in LN metastases (ALK, FGFR3, MET). Inversely, in 1 case, a KRAS mutation was found in LN but not in the primary tumour. All primary tumours were found PD-L1 positive while CD8+ T cells infiltrate varied. In the different examined LN samples, PD-L1 expression, CD8+ and PD1+ T cells infiltrate were not similar to the primary tumour. This preliminary prospective study shows the diversity of intra-tumour and LN mutations using routinely-used targeted NGS, concerning both mutated gene and allelic ratio. Further studies are needed to evaluate its prognostic impact.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Asamura H, Chansky K, Crowley J et al (2015) The International Association for the Study of Lung Cancer lung cancer staging project: proposals for the revision of the N descriptors in the forthcoming 8th edition of the TNM classification for lung cancer. J Thorac Oncol 10:1675–1684

    Article  CAS  PubMed  Google Scholar 

  2. Decaluwé H, De Leyn P, Vansteenkiste J et al (2009) Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival. Eur J Cardiothorac Surg 36:433–439

    Article  PubMed  Google Scholar 

  3. Arame A, Mordant P, Riquet M (2014) Pneumonectomy for stage IIIA NSCLC: a chance, not a calamity. Ann Thorac Surg 97:382

    Article  PubMed  Google Scholar 

  4. Riquet M, Mordant P, Pricopi C et al (2014) A review of 250 ten-year survivors after pneumonectomy for non-small-cell lung cancer. Eur J Cardiothorac Surg 45:876–881

    Article  Google Scholar 

  5. Legras A, Mordant P, Arame A et al (2014) Long-term survival of patients with pN2 lung cancer according to the pattern of lymphatic spread. Ann Thorac Surg 97:1156–1162

    Article  PubMed  Google Scholar 

  6. Zhang J, Fujimoto J, Zhang J et al (2014) Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 346:256–259

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. De Bruin EC, McGranahan N, Mitter R et al (2014) Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346:251–256

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Um S-W, Joung J-G, Lee H et al (2016) Molecular evolution patterns in metastatic lymph nodes reflect the differential treatment response of advanced primary lung cancer. Cancer Res 76:6568–6576

    Article  CAS  PubMed  Google Scholar 

  9. Pécuchet N, Legras A, Laurent-Puig P, Blons H (2016) Lung cancer molecular testing, what role for next generation sequencing and circulating tumor DNA. Ann Pathol 36:80–93

    Article  PubMed  Google Scholar 

  10. Garon EB, Rizvi NA, Hui R et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018–2028

    Article  Google Scholar 

  11. Mountain CF, Dresler CM (1997) Regional lymph node classification for lung cancer staging. Chest 111:1718–1723

    Article  CAS  PubMed  Google Scholar 

  12. Riquet M, Bagan P, Le Pimpec Barthes F et al (2007) Completely resected non-small cell lung cancer: reconsidering prognostic value and significance of N2 metastases. Ann Thorac Surg 84:1818–1824

    Article  PubMed  Google Scholar 

  13. Kozower BD, Larner JM, Detterbeck FC, Jones DR (2013) Special treatment issues in non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143:e369S–e399S

    Article  PubMed  Google Scholar 

  14. Robinson LA, Ruckdeschel JC, Wagner H et al (2007) Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132:243S–265S

    Article  PubMed  Google Scholar 

  15. Cancer bronchique non à petites cellules - Référentiel national de RCP - Ref (2017) RECOKBRNONPETCEL15 | Institut National Du Cancer. http://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Cancer-bronchique-non-a-petites-cellules-Referentiel-national-de-RCP. Accessed 26 June 2017

  16. Jamal-Hanjani M, Quezada SA, Larkin J, Swanton C (2015) Translational implications of tumor heterogeneity. Clin Cancer Res 21:1258–1266

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Hiley C, de Bruin EC, McGranahan N, Swanton C (2014) Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine. Genome Biol 15:453

    Article  PubMed  PubMed Central  Google Scholar 

  18. Baldia PH, Maurer A, Heide T et al (2016) Fibroblast growth factor receptor (FGFR) alterations in squamous differentiated bladder cancer: a putative therapeutic target for a small subgroup. Oncotarget 7:71429–71439

    Article  PubMed  PubMed Central  Google Scholar 

  19. Shirole NH, Pal D, Kastenhuber ER et al (2016) TP53 exon-6 truncating mutations produce separation of function isoforms with pro-tumorigenic functions. elife 6:e25532

    Article  Google Scholar 

  20. Benderra M-A, Aspeslagh S, Postel-Vinay S et al (2016) Acquired EGFR mutation as the potential resistance driver to Crizotinib in a MET-mutated tumor. J Thorac Oncol 11:e21–e23

    Article  PubMed  Google Scholar 

  21. Waqar SN, Cottrell CE, Morgensztern D (2015) MET mutation associated with responsiveness to crizotinib. J Thorac Oncol 10:e29–e31

    Article  PubMed  PubMed Central  Google Scholar 

  22. Koh J, Go H, Keam B et al (2015) Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status. Mod Pathol 28:1154–1166

    Article  CAS  PubMed  Google Scholar 

  23. D’Incecco A, Andreozzi M, Ludovini V et al (2015) PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer 112:95–102

    Article  CAS  PubMed  Google Scholar 

  24. Vieira T, Antoine M, Hamard C et al (2016) Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages. Lung Cancer Amst Neth 98:51–58

    Article  Google Scholar 

  25. Uruga H, Bozkurtlar E, Huynh TG et al (2016) Programmed cell death ligand (PD-L1) expression in stage II and III lung adenocarcinomas and nodal metastases. J Thorac Oncol 12:458–466

    Article  PubMed  Google Scholar 

  26. Kim M-Y, Koh J, Kim S et al (2015) Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: comparison with tumor-infiltrating T cells and the status of oncogenic drivers. Lung Cancer Amst Neth 88:24–33

    Article  Google Scholar 

  27. Taube JM, Klein A, Brahmer JR et al (2014) Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 20:5064–5074

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Françoise Le Pimpec-Barthes.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Additional information

Hélène Blons and Françoise Le Pimpec-Barthes share senior authorship.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Legras, A., Roussel, H., Mangiameli, G. et al. Mutational Diversity of Lung Cancer and Associated Lymph Nodes. An Exploratory Prospective Study of 4 Resected cIIIA-N2. Pathol. Oncol. Res. 25, 319–325 (2019). https://doi.org/10.1007/s12253-017-0352-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-017-0352-x

Keywords

Navigation